Bio-Works Technologies AB

About Us

Bio-Works enables scientists to achieve their purification goals, from laboratory research to large scale bioprocess production. Our vision is a biotech industry that embraces, develops and builds on new methods and novel ideas. WorkBeads™, Bio-Works’ next-generation, agarose-based products, are used to purify proteins, peptides and other biomolecules, resulting in purer therapies and safer diagnostics. Through collaboration with customers and partners, we develop purification solutions that make important medicines available and accessible to everyone. Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Nasdaq First North (“BIOWKS”), and FNCA Sweden AB, +46 (0) 8-528 00 399, info@fnca.se, is appointed Certified Adviser. For more information, www.bio-works.com.

Quotes

This project with Amicogen is incredibly interesting and creates very good conditions for a deeper collaboration in the future. With this agrement, Amicogen and Bio-Works will establish the first local production of agarose-based resins in South Korea

says Jonathan Royce, CEO at Bio-Works Technologies.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vator Securities: Bio-Works Technologies (BIOWKS:SS) – Outperform rating maintained and target price raised to SEK 15.8

Fri, Sep 20, 2019 07:52 CET

We believe that Bio-Works is now entering a new era as a professionally structured commercial player due to the following recent advancements; i) consecutive quarterly customer growth; ii) fast traction in the important Protein A segment shortly post launch of the product WorkBeads affimAb; and iii) activist-like investments by the new owners and board members Peter Ehrenheim (Chairman) and Thomas Eklund (Director), holding a total of 17% together with a group of similar investors. These seasoned investors bring significant industry-specific know-how and proven track records from GE

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Quotes

Vator Securities: Bio-Works Technologies (BIOWKS:SS) – Outperform rating maintained and target price raised to SEK 15.8

Subscribe